Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema

Oncotarget

Volumn 7, Issue 24, 2016, Pages 36021-36033

  Sehm, Tina ^a   Fan, Zheng ^a   Ghoochani, Ali ^a   Rauh, Manfred ^a   Engelhorn, Tobias ^a   Minakaki, Georgia ^a   Dörfler, Arnd ^a   Klucken, Jochen ^a   Buchfelder, Michael ^a   Eyüpoglu, Ilker Y ^a   Savaskan, Nicolai ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b BiMECON Ent   (Germany)

Author keywords

Brain swelling; Cancer; Glioblastoma; Tumor microenvironment

Indexed keywords

ANTIPORTER; GLUTAMATE ANTIPORTER XCT; SALAZOSULFAPYRIDINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE; GLUTAMATE TRANSPORTER; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; AUTOPHAGY; BRAIN EDEMA; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FERROPTOTIC CELL DEATH; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NEWBORN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CELL CULTURE; CELL DEATH; CELL SURVIVAL; COMPLICATION; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG EFFECTS; GLIOMA; METABOLISM; TUMOR CELL LINE; WISTAR RAT;

AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN EDEMA; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; RATS, WISTAR; SULFASALAZINE; TUMOR MICROENVIRONMENT;

EID: 84978141675     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8651     Document Type: Article

References (34)

1. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310:1842-50
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21:2683-710
3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005; 64:479-89
4. Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyupoglu IY. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med. 2008; 14:629-32
5. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013; 4:CD000545
6. Aruoma OI, Wasil M, Halliwell B, Hoey BM, Butler J. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their antiinflammatory effects? Biochem Pharmacol. 1987; 36:3739-42
7. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-29
8. Nielsen OH, Verspaget HW, Elmgreen J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther. 1988; 2:203-11
9. Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldof H, Van Krieken JH, Griffioen G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther. 1999; 13:1397-402
10. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998; 101:1163-74
11. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999; 116:602-9
12. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 2005; 25:7101-10
13. Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, Sontheimer H. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011; 17:1269-74
14. Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid MA, Eschbacher JM, Berens ME, Lahti AC, Nabors LB, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med. 2015; 7:289ra86
15. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016; 12:1-222
16. Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kogel D. The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Molecular cancer research. 2010; 8:1002-16
17. Rusten TE, Stenmark H. p62, an autophagy hero or culprit? Nature cell biology. 2010; 12:207-9
18. Eyupoglu IY, Hahnen E, Heckel A, Siebzehnrubl FA, Buslei R, Fahlbusch R, Blumcke I. Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. Technical note. Journal of neurosurgery. 2005; 102:738-44
19. Ghoochani A, Yakubov E, Sehm T, Fan Z, Hock S, Buchfelder M, Eyüpoglu IY, Savaskan NE. A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain. Oncotarget 2016; 7:1838-53. doi: 10.18632/oncotarget.6550
20. Savaskan NE, Fan Z, Broggini T, Buchfelder M, Eyupoglu IY. Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight. Current neuropharmacology. 2015; 13:258-65
21. Chung WJ, Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factorkappaB. J Neurochem. 2009; 110:182-93
22. Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol. 2000; 47:11-22
23. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol. 2010; 97:11-23
24. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999; 59:4383-91
25. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med. 2001; 7:1010-5
26. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 2007; 67:9463-71
27. Savaskan NE, Hahnen E, Eyupoglu IY. The x(c)(-) cystine/glutamate antiporter (xCT) as a potential target for therapy of cancer: yet another cytotoxic anticancer approach? J Cell Physiol. 2009; 220:531-2; author reply 3-4
28. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, Miwa A, Kurihara H, Nakazato Y, Tamura M, Sasaki T, Ozawa S. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med. 2002; 8:971-8
29. Robe PA, Martin D, Albert A, Deprez M, Chariot A, Bours V. A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer. 2006; 6:29
30. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M, Bours V. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 2009; 9:372
31. Sleire L, Skeie BS, Netland IA, Forde HE, Dodoo E, Selheim F, Leiss L, Heggdal JI, Pedersen PH, Wang J, Enger PO. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc(-), leading to glutathione depletion. Oncogene. 2015; 34:5951-9
32. Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. Journal of experimental & clinical cancer research. 2016; 35:23
33. Hatipoglu G, Hock SW, Weiss R, Fan Z, Sehm T, Ghoochani A, Buchfelder M, Savaskan NE, Eyupoglu IY. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment. Cancer science. 2015; 106:160-70
34. Savaskan NE, Borchert A, Brauer AU, Kuhn H. Role for glutathione peroxidase-4 in brain development and neuronal apoptosis: specific induction of enzyme expression in reactive astrocytes following brain injury. Free radical biology & medicine. 2007; 43:191-201